title: Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
abstract: OBJECTIVE
  To investigate the efficacy, safety, and dose response of three doses of ibandronate, given intermittently by intravenous (IV) injection every three months, in preventing postmenopausal osteoporosis.
  
  
  METHODS
  629 postmenopausal women, categorised according to time since menopause and baseline lumbar spine (L1-4) bone mineral density (BMD), were enrolled into a multicentre, double blind, placebo controlled trial. They were randomly allocated to receive IV ibandronate 0.5 mg, 1 mg or 2 mg, or placebo every three months. All women received daily calcium supplementation.
  
  
  RESULTS
  One year's treatment with intermittent IV ibandronate injections produced a dose dependent gain in mean (SD) lumbar spine BMD from baseline of 2.5 (2.5)%, 1.8 (2.6)%, and 1.0 (2.8)% in the groups receiving 2 mg, 1 mg, and 0.5 mg ibandronate, respectively, compared with a loss of BMD of 0.4 (2.4)% in the women in the placebo group; p=0.0001 for each ibandronate dose v placebo. Highest BMD gains occurred in women with osteopenia receiving 2 mg ibandronate. Similarly, at the hip, all three doses of ibandronate produced significantly better gains in BMD than placebo (p<0.05), with the greatest gains in the women with osteopenia receiving the 2 mg dose. Ibandronate concomitantly and dose dependently suppressed markers of bone turnover in comparison with placebo, and injections were well tolerated.
  
  
  CONCLUSIONS
  IV ibandronate injections, given every three months, may be an effective alternative to oral bisphosphonates and hormonal therapy in the prevention of bone loss in postmenopausal women.
authors.affiliation: CECOR AS, Haugesund, Norway. jacobas@cecor.no
authors.forename: J A
authors.initials: JA
authors.lastname: Stakkestad
authors.forename: L I
authors.initials: LI
authors.lastname: Benevolenskaya
authors.forename: J J
authors.initials: JJ
authors.lastname: Stepan
authors.forename: A
authors.initials: A
authors.lastname: Skag
authors.forename: A
authors.initials: A
authors.lastname: Nordby
authors.forename: E
authors.initials: E
authors.lastname: Oefjord
authors.forename: A
authors.initials: A
authors.lastname: Burdeska
authors.forename: I
authors.initials: I
authors.lastname: Jonkanski
authors.forename: P
authors.initials: P
authors.lastname: Mahoney
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density; D003094:Collagen / Q000097:blood / Q000652:urine; D024042:Collagen Type I; D018153:Czech Republic; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D007275:Injections, Intravenous; D008159:Lumbar Vertebrae; D008875:Middle Aged; D009664:Norway; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood / Q000652:urine; D012426:Russia; D018709:Statistics, Nonparametric
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D004164:Diphosphonates; D010281:Parathyroid Hormone; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D003094:Collagen; D000469:Alkaline Phosphatase; D000077557:Ibandronic Acid